Kevin Kovaleski brings 25 years of pharmaceutical experience specializing in understanding the unmet needs of rare-disease patients. Kevin spent the past 18 years in roles of increasing responsibility at CSL Behring. In his last position at CSL, Kevin was the VP and Head of Global Commercial Development for the Transplant Medicine Therapeutic Area (TA). In this role Kevin led the Global Marketing, Medical, Medical Communications and Market Access functions. Additionally, he served as Co-Lead of the Transplant Therapeutic Area Strategy team – a cross functional team of R&D and Commercial leaders – which was tasked with developing the long-term strategic direction for the TA. Prior to his time as VP, Kevin worked in various Global and US marketing roles in pulmonary (Alpha-1 Antitrypsin Deficiency), allergy/immunology (Hereditary Angioedema), bleeding disorders and maternal-fetal medicine. Before joining CSL, Kevin held marketing roles at Cephalon (Provigil) and Wyeth (Enbrel). Kevin began his pharma career in sales with Shire Pharmaceuticals, later becoming a marketing product manager responsible for launching Adderall XR. Kevin holds a B.S. degree in Finance from Pennsylvania State University. Along with his wife, four sons and two dogs, Kevin resides in the suburbs of Philadelphia.